#2167
Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan
Introduction:
Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Sakamoto Y,
Hijioka S,
Shibuya H,
Ito T,
Imamura M,
Keywords:
Streptozocin,
pNETs,
#1688
Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas
Introduction:
Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Hijioka S
Authors:
Hijioka S,
Hosoda W,
Matsuo k,
Ueno M,
Furukawa M,
Keywords:
NET G3,
NEC,
KRAS,
Rb,
#1582
Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction:
Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Authors:
Miki M,
Ito T,
Hijioka M,
Kawabe K,
Jensen R,
Keywords:
Pancreatic neuroendocrine tumors,
Chromogranin A,
Chromogranin B,
